摘要
生物技术和生物制药已经极大地改变了制药工业的格局。由于生物技术和生物制药在促进经济增长和产生社会效益方面存在的巨大潜力,使得生物经济的发展已成为美国政府优先考虑的民生问题。目前,美国制药和生物制药公司正在研发900多种生物制剂和疫苗,适用范围包括抗肿瘤、自身免疫性疾病,心血管疾病和感染性疾病等100多种疾病。本文综述当前美国生物制药领域的进展,并对美国政府的《国家生物经济蓝图》进行探讨。
Biotechnology and biopharmaceuticals have dramatically changed the pharmaceutical industry. Be- cause of its tremendous potential for economic growth and many societal benefits it offers, the bioeconomy has e- merged as a priority of the U. S. government. Currently, U.S. pharmaceutical/biopharmaceutical companies are developing more than 900 biopharmaceuticals and vaccines which target over 100 diseases including cancers, au- toimmune diseases, cardiovascular diseases and infectious diseases. In this minireview, current progresses in U. S. biopharmaceutical development and the National Bioeconomy Blueprint of the U. S. government are dis- cussed.
出处
《遵义医学院学报》
2014年第1期34-38,共5页
Journal of Zunyi Medical University
关键词
生物技术
生物制药
生物经济
biotechnology
biopharmaceuticals
bioeconomy
